HI
CRL icon

Horizon Investments’s Charles River Laboratories CRL Stock Holding History

Horizon Investments’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153K Buy
888
+67
+8% +$12.4K ﹤0.01% 1023
2025
Q4 		$164K Buy
821
+9
+1% +$1.63K ﹤0.01% 995
2025
Q3 		$127K Buy
812
+5
+0.6% +$794 ﹤0.01% 961
2025
Q2 		$122K Sell
807
-362
-31% -$48.3K ﹤0.01% 929
2025
Q1 		$176K Buy
1,169
+38
+3% +$6.37K 0.01% 563
2024
Q4 		$209K Sell
1,131
-123
-10% -$23.7K 0.01% 532
2024
Q3 		$247K Sell
1,254
-85
-6% -$17.7K 0.01% 504
2024
Q2 		$277K Buy
1,339
+79
+6% +$17.9K 0.01% 468
2024
Q1 		$341K Buy
1,260
+23
+2% +$5.49K 0.01% 424
2023
Q4 		$292K Buy
1,237
+52
+4% +$10.2K 0.01% 430
2023
Q3 		$232K Buy
1,185
+48
+4% +$9.85K 0.01% 473
2023
Q2 		$239K Buy
1,137
+176
+18% +$35K 0.01% 474
2023
Q1 		$194K Buy
961
+8
+0.8% +$1.81K 0.01% 523
2022
Q4 		$208K Buy
+953
New +$208K 0.01% 522

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Horizon Investments's CRL Position: Q1 2026 in Review

Horizon Investments increased its Charles River Laboratories (CRL) stake by 8.2% in Q1 2026, buying an estimated $12.4K and bringing the position to 888 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1023.

Horizon Investments first reported a position in CRL in Q4 2022 and has held it in 14 quarters since. The position peaked at $341K in Q1 2024. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Horizon Investments held 888 shares of Charles River Laboratories worth $153K as of Q1 2026.
  • Horizon Investments bought 67 Charles River Laboratories shares in Q1 2026, an estimated $12.4K.
  • Charles River Laboratories made up ﹤0.01% of Horizon Investments's portfolio in Q1 2026, its #1023 holding.
  • Horizon Investments first reported a position in Charles River Laboratories in Q4 2022 and has held it in 14 quarters since.
  • Horizon Investments's Charles River Laboratories position peaked at $341K in Q1 2024.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Horizon Investments's 13F filing for Q1 2026, filed 15 May 2026.